All about that (R&D) base: Bristol-Myers and Pfizer 4Q earnings
This article was originally published in Scrip
Executive Summary
Foreign currency exchange rates, generic competition and product sales (both good and bad) affected fourth quarter and full-year 2014 revenue and earnings for Bristol-Myers Squibb and Pfizer, but the companies assured investors on 27 January that their growth is dependent on what each of them sees as an improving research and development base.
You may also be interested in...
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.